New Route to Boost Pancreatic Cancer Treatment
News Jun 02, 2014
The scientists, based at the Cancer Research UK Cambridge Institute, have discovered that gemcitabine interacts with an important pathway in cells – called the Kennedy Pathway – which cells use to make special fats.
This research has identified that the drug is broken down in tumour cells by enzymes in the Kennedy Pathway, which might be an alternative way in which it works.
The findings also suggest that using linoleic acid in combination with gemcitabine increases the amount of gemcitabine in tumour cells, possibly making it more effective.
Study author, Professor Duncan Jodrell, group leader at the Cancer Research UK Cambridge Institute, said: “Gemcitabine is one of the drugs that we use commonly to treat pancreatic cancer, but the number of patients who benefit from it is still relatively small.”
“Improving our understanding of how gemcitabine interacts with cellular metabolism may allow us to develop combination treatments that improve outcomes for patients with pancreatic cancer.”
Around 8,800 people are diagnosed with pancreatic cancer in the UK every year but progress has been slow, with only around three per cent of people surviving their disease five years or more.
Nell Barrie, Cancer Research UK’s senior science communications officer, said: “Sadly, survival from pancreatic cancer is still low and we must do everything we can to fight this challenging disease with better treatments and ways to diagnose it early, when treatment is more effective.
“We’re making progress but it needs to be much faster, which is why Cancer Research UK is prioritising research into pancreatic cancer to save more lives from the disease.”
The research is published in the British Journal of Cancer (BJC).
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE